NCT00723749View on ClinicalTrials.gov

Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)

CompletedOBSERVATIONAL
Enrollment

384

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Opioid-Related DisordersOpiate DependenceDrug Abuse
Interventions
DRUG

Buprenorphine/Naloxone

"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."

Sponsors

Lead Sponsor

Indivior Inc.
All Listed Sponsors
lead

Indivior Inc.

INDUSTRY

NCT00723749 - Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603) | Biotech Hunter | Biotech Hunter